ReviewCancers2021
Pathology and Classification of SCLC.
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
92 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Effect of Exercise and Pulmonary Rehabilitation in Pre- and Post-Surgical Patients with Lung Cancer: Systematic Review and Meta-Analysis.Medicina (Kaunas, Lithuania) · 2024Pooled it
- Correlation between rs1800871, rs1800872 and rs1800896 Polymorphisms at IL-10 Gene and Lung Cancer Risk.Asian Pacific journal of cancer prevention : APJCP · 2024Pooled it
- Efficacy and safety of first-line immunotherapy plus chemotherapy in treating patients with extensive-stage small cell lung cancer: a Bayesian network meta-analysis.Frontiers in immunology · 2023Pooled it
- Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.Journal of the National Comprehensive Cancer Network : JNCCN · 2021Guideline
- Trial
- Immune Checkpoint Blockade Outcome in Small-Cell Lung Cancer and Its Relationship With Retinoblastoma Mutation Status and Function.JCO precision oncology · 2022Trial
- Loss of the RAGE function in hypoxic conditions exacerbates the malignant progression of lung adenocarcinoma via damage-associated molecular pattern signaling.Translational oncology · 2026Article
- Review
- The neuronal network of small cell lung cancer: a narrative review of the role of the nervous system in the pathogenesis and progression.Translational lung cancer research · 2026Review
- Immunohistochemistry as a Cornerstone in Lung Cancer Diagnosis: Subtyping Based on the 2021 World Health Organization Classification and Its Practical Application.World journal of oncology · 2026Article
- Clinicopathological significance of 5'-3' exoribonuclease 2 expression in small cell lung cancer tissues.Biochemistry and biophysics reports · 2026Article
- Development and validation of a nomogram for predicting overall survival in small cell lung cancer: a multicenter analysis integrating multimodal therapy and molecular pathology.Translational lung cancer research · 2026Article
- An Explainable Transformer-Based Framework for Lung Cancer Classification and Automated Radiology Report Generation from Multi-Slice CT Images.Biomedicines · 2026Article
- Neoadjuvant or conversion anti-PD-1/PD-L1 immunotherapy combined with chemotherapy improves 2-year survival and achieves high pathological complete response rate in patients with stage IIB-IIIB small-cell lung cancer.Translational lung cancer research · 2026Article
- Computational pathology features of immune architecture predict clinically relevant outcomes in small-cell lung cancer (SCLC).NPJ precision oncology · 2026Article
- Effect ofJournal of thoracic disease · 2026Article
- Pre-diagnostic body mass index trajectories and associations with lung cancer risk.American journal of epidemiology · 2026Article
- Activated Lymphocyte-Based Immunotherapy Plus Tomotherapy in an Older Patient with Stage III Lung Cancer: A Case Report.Geriatrics (Basel, Switzerland) · 2026Article
- Reconstructing the metastatic journey: functional circulating tumor cells and disseminated tumor cells based models for translational oncology.Journal of experimental & clinical cancer research : CR · 2026Review
- The role of gut microbiota in liver metastasis of small cell lung cancer: mechanisms and therapeutic implications.Frontiers in cellular and infection microbiology · 2026Review
32 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Lung cancer is consistently the leading cause of cancer-related death worldwide, and it ranks as the second most frequent type of new cancer cases diagnosed in the United States, both in males and females. One subtype of lung cancer, small cell lung carcinoma (SCLC), is an aggressive, poorly differentiated, and high-grade neuroendocrine carcinoma that accounts for 13% of all lung carcinomas. SCLC is the most frequent neuroendocrine lung tumor, and it is commonly presented as an advanced stage disease in heavy smokers. Due to its clinical presentation, it is typically diagnosed in small biopsies or cytology specimens, with routine immunostaining only. However, immunohistochemistry markers are extremely valuable in demonstrating neuroendocrine features of SCLC and supporting its differential diagnosis. The 2015 WHO classification grouped all pulmonary neuroendocrine carcinomas in one category and maintained the SCLC combined variant that was previously recognized. In this review, we explore multiple aspects of the pathologic features of this entity, as well as clinically relevant immunohistochemistry markers expression and its molecular characteristics. In addition, we will focus on characteristics of the tumor microenvironment, and the latest pathogenesis findings to better understand the new therapeutic options in the current era of personalized therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.